Search company, investor...

Founded Year

2008

Stage

Series B | Dead

About OD-OS

OD-OS, a subsidiary of SensoMotoric Instruments, develops its Navilas laser for the image-guided treatment of retinal disorders.

Headquarters Location

Warthestr. 21

Teltow, 14513,

Germany

+49 (3328) 31 282-100

Loading...

Loading...

OD-OS Patents

OD-OS has filed 10 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/30/2016

7/21/2020

Ophthalmology, Diseases of the eye and adnexa, Disorders of choroid and retina, Laser medicine, Vision

Grant

Application Date

12/30/2016

Grant Date

7/21/2020

Title

Related Topics

Ophthalmology, Diseases of the eye and adnexa, Disorders of choroid and retina, Laser medicine, Vision

Status

Grant

Latest OD-OS News

OD-OS Presents Navilas Laser System Pro 577s Navigated Retinal Laser

Oct 2, 2020

At the first virtual Euretina Congress, OD-OS presented the the Navilas Laser System 577s Pro for navigated retinal laser therapy. The Navilas Laser System 577s Pro supports precise and fast treatments of common retinal diseases, according to a company news release. It comes with the core tracking, mapping and registration technology of retina navigation combined with flexible upgrade options for advanced patient comfort, reporting, teaching, and advanced connectivity via integration of external diagnostic images and a DICOM interface. During and after Euretina, October 2-4, 2020, ophthalmologists can book a virtual demo of the Navilas Pro to see the handling in a simulated treatment scenario with the company’s clinical team. To request such a meeting via the OD-OS booth at Euretina 2020 or via the OD-OS website www.od-os.com (independent from Euretina participation). In many clinics, retinal laser treatments are still performed with manually operated single spot or multispot laser systems which only provide a small slit lamp view on the retina. The high-resolution color fundus image of the all-digital Navilas Laser System provides better overview during treatment, according to OD-OS. Caution zones on sensible areas like the fovea and the optic disk combined with the integrated eye tracking allow for tracked and therefore highly precise lasering.1 As a result, over the past years navigated laser technology has been adopted by leading institutions around the world. The Navilas Pro combines the advantages of retina navigation with a competitive price point while flexibly growing with application needs. Navilas supports panretinal photocoagulation with uniform spot distribution which is faster and less painful for patients than PRP treatment with conventional slit-lamp lasers.2,3 This way, doctors may perform more treatments in less time contributing to higher economic efficiency. “Our experience in everyday clinical practice shows that the treatment with Navilas is much faster and, based on this, reduces the number of laser sessions, so that we can cope better with the steadily growing number of patients. Our patients report less pain than with conventional lasers,” Prof. Albert Augustin, Städtisches Klinikum Karlsruhe, said in a company news release. “As therapists, we value, among other things, the targeted spot planning with defined spacing. This increases safety during focal treatments and supports secure closure of foramina even in the far periphery.” To learn more about the digital ecosystem of navigated retinal laser including the Navilas Pro, visit https://www.od-os.com/navilas-laser-system/ References Liesfeld, Ben et al: Navigating Comfortably across the Retina; World Congress on Medical Physics and Biomedical Engineering, 2009 Chhablani J, Mathai A, Rani P, Gupta V, Arevalo JF, Kozak I. Comparison of conventional pattern and novel navigated panretinal photocoagulation in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014 May 1;55(6):3432-8. doi: 10.1167/iovs.14-13936. PubMed PMID: 24787564. Amoroso F, Pedinielli A, Astroz P, et al. Comparison of pain experience and time required for pre-planned navigated peripheral laser versus conventional multispot laser in the treatment of diabetic retinopathy. Acta Diabetol. November 2019. doi:10.1007/s00592-019-01455-x Related Content

OD-OS Frequently Asked Questions (FAQ)

  • When was OD-OS founded?

    OD-OS was founded in 2008.

  • Where is OD-OS's headquarters?

    OD-OS's headquarters is located at Warthestr. 21, Teltow.

  • What is OD-OS's latest funding round?

    OD-OS's latest funding round is Series B.

  • Who are the investors of OD-OS?

    Investors of OD-OS include MIG Verwaltungs, BC Brandenburg Capital, STST, SMI and IBG Beteiligungsfonds.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.